Alzheimer's disease: new bad meds and a new FDA-approved med that may help
A couple of new articles on treatment of Alzheimer’s disease came out in the last couple of weeks. The first is an investigative report on some monoclonal antibodies that delayed symptoms of Alzheimer’s for a few months but at a remarkably high risk of very serious adverse events in an ethically fraught study; the second is potentially redeploying a schizophrenia drug as a treatment for Alzheimer’s --------------------------------------------------------------------- New York times had a very recent and remarkably disturbing article on new FDA-approved Alzheimer’s Disease drugs that had significantly more serious adverse effects than benefits: https://www.nytimes.com/2024/10/23/health/alzheimers-drug-brain-bleeding.html?smid=nytcore-ios-share&referringSource=articleShare Details : -- the drugmaker Eisai in 2021 recruited 2000 volunteers to test their experimental Alzheimer’s drug BAN2401, a monoclonal antibody targeted to eliminate brain beta-a...